Still SF [Two-Stage / GS Designs]

posted by ElMaestro  – Denmark, 2016-10-06 22:13 (1932 d 14:30 ago) – Posting: # 16702
Views: 11,742

Hello VStus,

» But back to reality: isn't it more practical in case of HVD to perform pilot on development with let's say 50% power (wondering: replicated pilot to keep reasonable small population?), better understand in-vitro in-vivo relationship, optimize formulation and than run replicate scaled trial? In 2-stage we also need to wait for results from the 1st stage...

Yes
Nitpicking: you perform a 2-stage trial or a pilot trial because you do not know the variability, right? Which means the "let's say 50% power" in actuality means guessworking. Optimizing the formulation on basis of a pilot trial with inherently low power (=high uncertainty on the PE) is in scientific terms as solid as tarot cards or crystal healing.
I read on LinkedIn the other day: "The flat earth society has members all over the globe" :-D:-D:-D

OK, surely I will get in trouble for this post.
:pirate:

Pass or fail!
ElMaestro

Complete thread:

Activity
 Admin contact
21,833 posts in 4,568 threads, 1,554 registered users;
online 6 (0 registered, 6 guests [including 4 identified bots]).
Forum time: Friday 11:43 CET (Europe/Vienna)

No problem can stand the assault of sustained thinking.    Voltaire

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5